CML 25 Years Later — Poised for Another Breakthrough?
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2407913 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Elisabetta Abruzzese. Beteiligte Einrichtung: From the Department of Hematology, S. Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma 2, Rome. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
In 1960, the discovery of the Philadelphia chromosome in patients with chronic myeloid leukemia (CML) opened the door to the development of insights on the role of genes in human cancers. This pivotal finding was followed by the identification of the 9;22 chromosomal translocation and the BCR::ABL1 fusion gene, encoding an active tyrosine kinase that drives the onset of CML. This discovery paved the way for developing tyrosine kinase inhibitors (TKIs) in the early 2000s, revolutionizing cancer treatment. 1 The first TKI, imatinib, introduced a molecular approach to diagnosing, treating, and monitoring cancers, which showed how specific genetic mutations and aberrant . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Hematology, S. Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma 2, Rome.
Zitieren
APA
Abruzzese, E. (2024). CML 25 Years Later — Poised for Another Breakthrough?. New England Journal of Medicine. https://doi.org/10.1056/nejme2407913
Vancouver
Abruzzese E. CML 25 Years Later — Poised for Another Breakthrough?. New England Journal of Medicine. 2024. doi:10.1056/nejme2407913
BibTeX
@article{Abruzzese2024,
author = {Abruzzese, Elisabetta},
title = {CML 25 Years Later — Poised for Another Breakthrough?},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2407913}
}
EUVIMED